- Open Access
Control of tick infestations and pathogen prevalence in cattle and sheep farms vaccinated with the recombinant Subolesin-Major Surface Protein 1a chimeric antigen
- Alessandra Torina1, 2,
- Juan A Moreno-Cid3,
- Valeria Blanda1,
- Isabel G Fernández de Mera3,
- José M Pérez de la Lastra3,
- Salvatore Scimeca1,
- Marcellocalogero Blanda1,
- Maria Elena Scariano1,
- Salvatore Briganò1,
- Rosaria Disclafani1,
- Antonio Piazza1,
- Joaquín Vicente3,
- Christian Gortázar3,
- Santo Caracappa1,
- Rossella Colomba Lelli1 and
- José de la Fuente3, 4Email author
© Torina et al.; licensee BioMed Central Ltd. 2014
Received: 13 November 2013
Accepted: 5 January 2014
Published: 8 January 2014
Despite the use of chemical acaricides, tick infestations continue to affect animal health and production worldwide. Tick vaccines have been proposed as a cost-effective and environmentally friendly alternative for tick control. Vaccination with the candidate tick protective antigen, Subolesin (SUB), has been shown experimentally to be effective in controlling vector infestations and pathogen infection. Furthermore, Escherichia coli membranes containing the chimeric antigen composed of SUB fused to Anaplasma marginale Major Surface Protein 1a (MSP1a) (SUB-MSP1a) were produced using a simple low-cost process and proved to be effective for the control of cattle tick, Rhipicephalus (Boophilus) microplus and R. annulatus infestations in pen trials. In this research, field trials were conducted to characterize the effect of vaccination with SUB-MSP1a on tick infestations and the prevalence of tick-borne pathogens in a randomized controlled prospective study.
Two cattle and two sheep farms with similar geographical locations and production characteristics were randomly assigned to control and vaccinated groups. Ticks were collected, counted, weighed and classified and the prevalence of tick-borne pathogens at the DNA and serological levels were followed for one year prior to and 9 months after vaccination.
Both cattle and sheep developed antibodies against SUB in response to vaccination. The main effect of the vaccine in cattle was the 8-fold reduction in the percent of infested animals while vaccination in sheep reduced tick infestations by 63%. Female tick weight was 32-55% lower in ticks collected from both vaccinated cattle and sheep when compared to controls. The seroprevalence of Babesia bigemina was lower by 30% in vaccinated cattle, suggesting a possible role for the vaccine in decreasing the prevalence of this tick-borne pathogen. The effect of the vaccine in reducing the frequency of one A. marginale msp4 genotype probably reflected the reduction in the prevalence of a tick-transmitted strain as a result of the reduction in the percent of tick-infested cattle.
These data provide evidence of the dual effect of a SUB-based vaccine for controlling tick infestations and pathogen infection/transmission and provide additional support for the use of the SUB-MSP1a vaccine for tick control in cattle and sheep.
Tick infestations affect animal health and production worldwide, both for the impact on animal weight gain and milk production and for the pathogens transmitted by these ectoparasites [1–4]. Acaricides are a major component of integrated tick control strategies, but their application has had limited efficacy in reducing tick infestations and is often accompanied by serious drawbacks, including the selection of acaricide-resistant ticks, environmental contamination and contamination of milk and meat products with drug residues . All of these issues reinforce the need for alternative approaches to control tick infestations and pathogen transmission, including the use of vaccines with tick antigens [5–7].
In the early 1990s, commercial vaccines containing the recombinant Rhipicephalus (Boophilus) microplus BM86 gut antigen were developed and commercialized for the control of cattle tick infestations . These vaccines proved to be a cost-effective alternative for cattle tick control through the reduction of the number of engorged female ticks, their weight and reproductive capacity and the prevalence of some tick-borne pathogens [1, 8]. However, BM86-based vaccines have limited efficacy against other tick species and thus new vaccines are needed for the control of multiple tick species infestations, which occur in many areas used for animal husbandry [5, 6, 8].
Recently, Subolesin (SUB) was discovered as a new candidate tick protective antigen [9, 10]. Vaccination trials with recombinant SUB and its ortholog in insects, Akirin, demonstrated effective control of arthropod vector infestations in various hard and soft tick species, mosquitoes, sand flies, poultry red mites and sea lice by reducing their numbers, weight, oviposition, fertility and/or molting and also reduced tick infection with tick-borne pathogens, Anaplasma phagocytophilum, Anaplasma marginale, Babesia bigemina and Borrelia burgdorferi. Furthermore, the chimeric antigen, tick SUB fused with A. marginale Major Surface Protein 1a (MSP1a; SUB-MSP1a), was produced in Escherichia coli using a simple and low-cost process. Use of a vaccine with bacterial membranes containing the SUB-MSP1a chimera with surface-exposed SUB provided control of R. microplus and R. annulatus tick infestations [12, 13], and this vaccine formulation was proposed as a low-cost and effective alternative means of tick control.
However, vaccination trials with SUB-MSP1a were conducted under controlled conditions and only in cattle experimentally infested with R. microplus and R. annulatus, which limit the assessment of the potential impact of this vaccine for the control of tick infestations and the prevalence of tick-borne pathogens under field conditions. To address these limitations, herein we conducted field trials on cattle and sheep farms in order to assess the efficacy of the SUB-MSP1a vaccine for the control of multiple tick species and tick-borne pathogens.
Experimental design and rationale
The field trial was designed to characterize the effect of vaccination with SUB-MSP1a on tick infestations and the prevalence of tick-borne pathogens at the DNA and serological levels in a randomized controlled prospective study. Two cattle and two sheep farms with similar geographical locations and production characteristics were randomly assigned as control or vaccinated herds. These farms were followed for one year prior to vaccination and 9 months after vaccination. Vaccine trials were approved by the Italian Ministry of Health (Direzione Generale della Sanita’ Aimale e dei Farmaci Veterinari, permit no. DGSAF 0002336-P-08/02/2011).
Vaccine preparation and vaccination
Unless otherwise indicated, all reagents used in this work were purchased either from Sigma-Aldrich (St Louis, MO, USA) or VWR International Eurolab S.L. (Mollet del Vallés, Barcelona, Spain). The vaccine containing bacterial membranes with surface-exposed R. microplus SUB-MSP1a chimeric antigens was prepared as previously described . Briefly, recombinant E. coli JM109 cells transformed with the pMBXAF3 expression vector were propagated in 1 litre flasks containing 250 ml Luria–Bertani (LB) broth supplemented with 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, 50 μg/ml ampicillin and 0.4% glucose (Laboratorios CONDA S.A., Madrid, Spain) for 2 h at 37ºC and 200 rpm and then for 5.5 h after addition of 0.5 mM final concentration of isopropyl-β-d-thiogalactopyranoside (IPTG) for induction of recombinant protein production . The cells were harvested by centrifugation at 10,000 x g for 15 min at 4ºC and then 1 g of cell pellet was resuspended in 5 ml of disruption buffer (100 mM Tris HCl, pH 7.5, 150 mM NaCl, 1 mM PMSF, 5 mM MgCl2 · 6H2O and 0.1% (v/v) Triton X-100) and disrupted using a cell sonicator (Model MS73; Bandelin Sonopuls, Berlin, Germany). After disruption, the insoluble protein fraction containing the membrane-bound SUB-MSP1a was collected by centrifugation at 21, 500 x g for 15 min at 4°C. The membrane-bound insoluble protein fraction containing over 50% of total proteins corresponding to the SUB-MSP1a chimera was resuspended in PBS, pH 7.4 and adjuvated in Montanide ISA 50 V2 (Seppic, Paris, France) at a concentration of 125 μg/ml.
All cattle and sheep present in the farms, including newborns at month 4 of age and adults imported during the trial were treated. Animals in cattle farm G and sheep farm C were vaccinated with two immunization doses of 1 ml containing 100 μg of the antigen preparation. Animals in cattle farm M and sheep farm L were injected with a similar volume of adjuvant/saline alone as control. Injections were done intramuscularly in the back of the animals using a 2.5-ml syringe and an 18G needle. Cattle in vaccinated and control farms were vaccinated or injected with adjuvant/saline on March 19th and April 20th, 2012. Sheep in vaccinated and control farms were vaccinated or injected with adjuvant/saline on March 13th and April 12th, 2012. Cattle in both vaccinated and control farms were treated with tilmicocin to prevent pneumonia prior to the first vaccination or adjuvant/saline injection following the manufacturer’s recommendations (TILMI-kel; KELA Laboratoria, Hoogstraten, Belgium). No contraindications have been described for this or similar products with respect to response to vaccination.
In each farm, ticks and EDTA-treated and untreated blood samples were collected from all animals before each immunization and four weeks after the last immunization and then monthly from randomly selected individuals representing 10% of the animals present in the farm. Serum was separated from blood samples by centrifugation and stored with EDTA-treated blood samples at −20°C.
Characterization of tick infestations
Collected ticks were counted for each animal, identified by morphological features using standard taxonomic keys for Italian Ixodidae  and preserved in 70% ethanol. Replete female ticks were weighed individually and the weights (mg) were compared between animals in the vaccinated farm before and after vaccination and between vaccinated and control farms by Student’s t-test with unequal variance (p = 0.05). Tick infestations (ticks/animal) were modeled separately for cattle and sheep using a generalized lineal model with binomial function and logit error with the dependent variables presence/absence of ticks and sampling time and farm as explanatory variables (p = 0.01; SPSS Statistics version 19, Surrey, UK). Tick infestations (ticks/animal) were compared between vaccinated and control animals using an ANOVA test (p = 0.05). The percent of animals infested with ticks before and after vaccination was compared between vaccinated and control farms by Student’s t-test with unequal variance (p = 0.05).
Pathogen DNA identification by PCR
DNA was extracted from EDTA-treated blood samples using the PureLink Genomic Mini kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. DNA samples were analyzed by PCR as reported previously to detect the presence of DNA from Anaplasma spp.  in all samples and positive samples were then analyzed for A. marginale/A. ovis[17, 18] and A. phagocytophilum DNA. The presence of DNA from A. marginale[17, 18], Babesia bovis, B. bigemina and Theileria annulata was analyzed in cattle only while DNA from A. ovis, B. ovis and T. ovis was characterized in sheep only. Coxiella burnetii and A. phagocytophilum DNA was characterized in both cattle and sheep samples.
PCRs were performed in a reaction buffer containing 1.5 mM MgCl2, 0.2 mM dNTPs, forward and reverse primers at a concentration of 0.4 mM, and 0.025 U/μl of Taq polymerase (5 U/μl) (Promega, Madison, WI, USA). For each reaction, a positive control consisting of pathogen DNA and a negative control in which DNA was replaced by water were used. PCR products were visualized after agarose gel electrophoresis containing 10 μg/ml ethidium bromide. Pathogen DNA prevalence (% positive animals) was compared between animals in the vaccinated farm before and after vaccination and between vaccinated and control farms by Student’s t-test with unequal variance (p = 0.05).
Serum antibody titers were determined using antigen-specific indirect ELISAs against SUB-MSP1a or SUB [12, 25]. Briefly, purified antigens (0.1 μg/well) were used to coat ELISA plates overnight at 4°C. Plates were then washed three times with PBS/0.1% tween 20, pH 7.2. Sera were serially diluted to 1:100 and 1:1000 in PBS/0.5% Tween 20, pH 7.2 (PBST) and 10% fetal bovine serum (Sigma). The plates were incubated with the diluted sera for 1 hr at 37°C, washed three times with PBST and then incubated with 1:10,000 rabbit anti-bovine immunoglubolin G (IgG)-horseradish peroxidase conjugate (Sigma) for 1 hr at 37°C. Plates were washed three times with PBST and the color reaction was developed after incubation at 37°C with 200 μl of the substrate SIGMAFAS™OPD (Sigma). The reaction was stopped after 20 min with a solution of 4N sulphuric acid and the O.D.450nm was determined. Antibody titers were considered positive when they yielded an O.D.450nm value at least twice as high as the preimmune serum. Antibody titers were expressed as the O.D.450nm value for the highest serum dilution (1:1000) and compared between vaccinated and placebo control cattle using an ANOVA test (p = 0.05).
Bovine and ovine serum samples were analyzed using commercial ELISA kits for the presence of antibodies against A. marginale/A. ovis (VMRD, Pullman, WA, USA), B. bigemina (Svanova Biotech AB, Uppsala, Sweden) and C. burnetii (ID.vet, Montpellier, France) following manufacturer’s recommendations. The presence of antibodies against T. annulata was evaluated by immunofluorescence using antigen slides prepared as described previously . Pathogen seroprevalence (% positive animals) was compared between animals in the vaccinated farm before and after vaccination and between vaccinated and control farms by Student’s t-test with unequal variance (p = 0.05).
PCR amplification and sequencing of A. marginale and A. ovis major surface protein 4 (msp4) gene
Total DNA was extracted from EDTA-treated blood samples and analyzed by msp4 PCR as described before  in all samples positive for Anaplasma spp. DNA. The msp4 amplicons were purified using the MinElute PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced (Secugen S.L., Madrid, Spain). Genotype frequencies were calculated as the percent of animals positive for each genotype. A correlation analysis was conducted to analyze genotype frequencies in time using Excel. The msp4 sequences were aligned using the program AlignX (Vector NTI Suite V 5.5, InforMax, North Bethesda, MD, USA). The msp4 sequences were submitted to the GenBank under accession numbers [GenBank: KF739427-KF739433].
Results and Discussion
Antibody response in cattle and sheep vaccinated with the SUB-MSP1a antigen
Effect of vaccination on tick infestations on cattle and sheep
Taken together, these results showed that the main effect of the SUB-MSP1a vaccine in cattle was the reduction in the percent of infested animals but not in the tick infestation rate of these animals. On the contrary, vaccination in sheep did not affect the percent of infested animals but reduced tick infestations. The reduction of female tick weight was observed in ticks collected from both vaccinated cattle and sheep.
Effect of vaccination on the prevalence of tick-borne pathogens
The ultimate goal of tick vaccines is to reduce the prevalence of tick-borne diseases . Tick vaccines have been shown to reduce the prevalence of tick-borne pathogens by reducing tick infestations and thus the exposure of susceptible hosts to pathogen transmission (e.g. BM86-based vaccine; ) and through reduction of tick vector capacity (e.g. SUB; [10, 11]). Importantly, vaccination with SUB has shown that the vaccine reduces both tick infestations and pathogen infection/transmission, thus having a dual effect on reducing tick-borne diseases [11, 29].
In our trial, the prevalence of tick-borne pathogens that has been described infecting cattle and/or sheep in Sicily [28, 30–33] was analyzed at the DNA (A. marginale, A. ovis, A. phagocytophilum, B. bovis, B. bigemina, B. ovis, T. annulata, T. ovis and C. burnetii) and serology (Anaplasma spp., B. bigemina, T. annulata and C. burnetii) levels. The prevalence of A. marginale, B. bovis, B. bigemina and T. annulata was analyzed in cattle only while the prevalence of A. ovis, B. ovis and T. ovis was characterized in sheep only. C. burnetii and A. phagocytophilum prevalence were characterized in both cattle and sheep.
In summary, the results of vaccination with SUB-MSP1a on the prevalence of tick-borne pathogens suggested a role for the vaccine in decreasing B. bigemina seroprevalence in cattle. This finding is in agreement with the results of previous studies and demonstrated that vaccination with SUB reduces B. bigemina DNA levels in ticks fed on infected and vaccinated cattle [25, 29]. Additionally, this result may reflect the reduction in the percent of infested animals shown in cattle vaccinated with SUB-MSP1a. However, in contrast to previous results in cattle vaccinated with SUB [25, 29], vaccination with SUB-MSP1a did not reduce the prevalence for A. marginale. In sheep, the only effect of the vaccine was on the decrease of C. burnetii seroprevalence in vaccinated but not in control animals after vaccination. However, this result may reflect better farm management and animal health conditions in sheep farm C when compared to farm L, factors known to affect the prevalence of C. burnetii[34, 35] and other tick-borne pathogens . As shown in field trials using BM86-based commercial vaccines , the reduction in tick infestations in sheep vaccinated with SUB-MSP1a would require several years of vaccination before it could decrease the prevalence of some tick-borne pathogens.
Characterization of the A. marginale and A. ovis msp4 genotypes in cattle and sheep
A. marginale and A. ovis are transmitted not only biologically by ticks, but also mechanically by biting insects and blood contaminated fomites . Therefore, despite the fact that vaccination with SUB-MSP1a did not affect Anaplasma spp. prevalence in this trial, we characterized A. marginale and A. ovis msp4 genotypes trying to identify a possible effect of the vaccine on some genotypes likely transmitted by ticks. For this analysis, we used the msp4 genetic marker, which has been used before for the characterization of genetic diversity in these species .
To our knowledge, this is the first vaccine trial assessing the control of multiple tick species infestations and pathogen prevalence in cattle and sheep and the first field trial using the SUB-MSP1a vaccine. The main findings of these studies were that (a) both cattle and sheep developed antibodies in response to vaccination; (b) the main effect of the vaccine in cattle was the reduction in the percent of infested animals but not in the tick infestation rate in these animals; (c) vaccination in sheep did not affect the percent of infested animals but reduced tick infestations; (d) female tick weight was lower in ticks collected from both vaccinated cattle and sheep when compared to controls; (e) lower B. bigemina seroprevalence in vaccinated cattle suggested a role for the vaccine in decreasing the prevalence of this tick-borne pathogen; and (f) the effect of the vaccine in reducing the frequency of one A. marginale genotype probably reflected the reduction in the prevalence of a tick-transmitted strain as a result of the reduction in the percent of tick-infested cattle. The lower female tick weights are likely to impact and decrease tick populations over time because it has been well documented that lower female tick engorgement weights correlate with the oviposition of smaller egg masses. This trend would likely reduce tick populations over time. As has been noted previously, tick vaccines are likely to be an important component of integrated tick control methods and would likely reduce the use of acaricides.
These results provide new evidence to support that SUB-based vaccines have the dual effect of controlling tick infestations and pathogen infection/transmission, thus reducing tick populations and their vector capacity to impact on the control of tick-borne diseases . These results also provide additional support for the use of the vaccine containing E. coli membranes with the surface-exposed SUB-MSP1a chimera as a low-cost and effective alternative for tick control in cattle and sheep, even under conditions with multiple tick species infestations and the prevalence of several tick-borne pathogens.
We would like to thank Rosalia D’Agostino, Rosa Filippi and Nicola Galati (Intituto Zooprofilattico Sperimentale della Sicilia, Palermo, Sicily, Italy) for technical assistance. This research was supported by the Italian Ministry of Health IZS, project SI09/09 and BFU2011-23896 grant to JF. J.A. Moreno-Cid was funded by the Consejería de Educación y Ciencia, JCCM, Spain (project PEII09-0118-8907) as a recipient of a JCCM fellowship.
- de la Fuente J, Rodríguez M, Redondo M, Montero C, García-García JC, Méndez L, Serrano E, Valdés M, Enríquez A, Canales M, Ramos E, de Armas CA, Rey S, Rodríguez JL, Artiles M, García L: Field studies and cost-effectiveness analysis of vaccination with GavacTM against the cattle tick Boophilus microplus. Vaccine. 1998, 16: 366-373. 10.1016/S0264-410X(97)00208-9.View ArticlePubMedGoogle Scholar
- de la Fuente J, Estrada-Peña A, Venzal JM, Kocan KM, Sonenshine DE: Overview: ticks as vectors of pathogens that cause disease in humans and animals. Front Biosci. 2008, 13: 6938-6946.View ArticlePubMedGoogle Scholar
- Caracappa S: Livestock production and animal health in Sicily, Italy. Parassitologia. 1999, 41 (Suppl. 1): 17-23.PubMedGoogle Scholar
- Graf JF, Gogolewski R, Leach-Bing N, Sabatini GA, Molento MB, Bordin EL, Arantes GJ: Tick control: an industry point of view. Parasitol. 2004, 129: S427-S442. 10.1017/S0031182004006079.View ArticleGoogle Scholar
- de la Fuente J, Kocan KM: Strategies for development of vaccines for control of ixodid tick species. Parasite Immunol. 2006, 28: 275-283. 10.1111/j.1365-3024.2006.00828.x.View ArticlePubMedGoogle Scholar
- Willadsen P: Tick control: thoughts on a research agenda. Vet Parasitol. 2006, 138: 161-168. 10.1016/j.vetpar.2006.01.050.View ArticlePubMedGoogle Scholar
- de la Fuente J: Vaccines for vector control: exciting possibilities for the future. Vet J. 2012, 194: 139-140. 10.1016/j.tvjl.2012.07.029.View ArticlePubMedGoogle Scholar
- de la Fuente J, Almazán C, Canales M, de la Lastra JM P, Kocan KM, Willadsen P: A ten-year review of commercial vaccine performance for control of tick infestations on cattle. Anim Health Res Rev. 2007, 8: 23-28. 10.1017/S1466252307001193.View ArticlePubMedGoogle Scholar
- Almazán C, Kocan KM, Bergman DK, Garcia-Garcia JC, Blouin EF, de la Fuente J: Identification of protective antigens for the control of Ixodes scapularis infestations using cDNA expression library immunization. Vaccine. 2003, 21: 1492-1501. 10.1016/S0264-410X(02)00683-7.View ArticlePubMedGoogle Scholar
- de la Fuente J, Moreno-Cid JA, Canales M, Villar M, de la Lastra JM P, Kocan KM, Galindo RC, Almazán C, Blouin EF: Targeting arthropod subolesin/akirin for the development of a universal vaccine for control of vector infestations and pathogen transmission. Vet Parasitol. 2011, 181: 17-22. 10.1016/j.vetpar.2011.04.018.View ArticlePubMedGoogle Scholar
- de la Fuente J, Moreno-Cid JA, Villar M, Galindo RC, Almazán C, Kocan KM, Merino O, de la Lastra JM P, Estrada-Peña A, Blouin EF: Subolesin/Akirin vaccines for the control of arthropod vectors and vector-borne pathogens. Transb Emerg Dis. 2013, in pressGoogle Scholar
- Almazán C, Moreno-Cantú O, Moreno-Cid JA, Galindo RC, Canales M, Villar M, de la Fuente J: Control of tick infestations in cattle vaccinated with bacterial membranes containing surface-exposed tick protective antigens. Vaccine. 2012, 30: 265-272. 10.1016/j.vaccine.2011.10.102.View ArticlePubMedGoogle Scholar
- Canales M, Moreno-Cid JA, Almazán C, Villar M, de la Fuente J: Bioprocess design and economics of recombinant BM86/BM95 antigen production for anti-tick vaccines. Biochem Eng J. 2010, 52: 79-90. 10.1016/j.bej.2010.07.008.View ArticleGoogle Scholar
- Canales M, Almazán C, de la Lastra JM P, de la Fuente J: Anaplasma marginale major surface protein 1a directs cell surface display of tick BM95 immunogenic peptides on Escherichia coli. J Biotechnol. 2008, 135: 326-332. 10.1016/j.jbiotec.2008.05.006.View ArticlePubMedGoogle Scholar
- Manilla G: Fauna D’Italia. Acari: Ixodida. 1998, Calderini, Bologna, firstGoogle Scholar
- Stuen S, Nevland S, Moum T: Fatal cases of tick-borne fever (TBF) in sheep caused by several 16S rRNA gene variants of Anaplasma phagocytophilum. Ann NY Acad Sci. 2003, 990: 443-434.View ArticleGoogle Scholar
- de la Fuente J, Vicente J, Höfle U, Ruiz-Fons F, de Mera IG F, Van Den Bussche RA, Kocan KM, Gortazar C: Anaplasma infection in free-ranging Iberian red deer in the region of Castilla-La Mancha, Spain. Vet Microbiol. 2004, 100: 163-173. 10.1016/j.vetmic.2004.02.007.View ArticlePubMedGoogle Scholar
- Torina A, Agnone A, Blanda V, Alongi A, D'Agostino R, Caracappa S, Marino AM, Di Marco V, de la Fuente J: Development and validation of two PCR tests for the detection of and differentiation between Anaplasma ovis and Anaplasma marginale. Ticks Tick Borne Dis. 2012, 3: 283-287. 10.1016/j.ttbdis.2012.10.033.View ArticlePubMedGoogle Scholar
- de la Fuente J, Massung RF, Wong SJ, Chu FK, Lutz H, Meli M, von Loewenich FD, Grzeszczuk A, Torina A, Caracappa S, Mangold AJ, Naranjo V, Stuen S, Kocan KM: Sequence analysis of the msp4 gene of Anaplasma phagocytophilum strains. J Clin Microbiol. 2005, 43: 1309-1317. 10.1128/JCM.43.3.1309-1317.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Figueroa JV, Chieves LP, Johnson GS, Buening GM: Multiplex polimerase chain reaction based assay for the detection of Babesia bigemina, Babesia bovis and Anaplasma marginale DNA in bovine blood. Vet Parasitol. 1993, 50: 69-81. 10.1016/0304-4017(93)90008-B.View ArticlePubMedGoogle Scholar
- D’Oliveira C, van der Weide M, Habela MA, Jacquiet P, Jongejan F: Detection of Theileria annulata in blood samples of carriers by PCR. J Clin Microbiol. 1995, 33: 1665-2669.Google Scholar
- Aktaş M, Altay K, Dumanli N: Development of a polymerase chain reaction method for diagnosis of Babesia ovis infection in sheep and goats. Vet Parasitol. 2005, 133: 277-281. 10.1016/j.vetpar.2005.05.057.View ArticlePubMedGoogle Scholar
- Altay K, Dumanli N, Holman PJ, Aktas M: Detection of Theileria ovis in naturally infected sheep by nested PCR. Vet Parasitol. 2005, 127: 99-104. 10.1016/j.vetpar.2004.09.012.View ArticlePubMedGoogle Scholar
- To H, Kako N, Zhang GQ, Otsusa H, Ogawa M, Ochiai O, Nguyen Sa V, Yamaguchi T, Fukushi H, Nagaoka N, Akiyama M, Amano K, Hirai K: Q fever pneumonia in children in Japan. J Clin Microbiol. 1996, 34: 647-651.PubMed CentralPubMedGoogle Scholar
- Merino O, Almazán C, Canales M, Villar M, Moreno-Cid JA, Galindo RC, de la Fuente J: Targeting the tick protective antigen subolesin reduces vector infestations and pathogen infection by Anaplasma marginale and Babesia bigemina. Vaccine. 2011, 29: 8575-8579. 10.1016/j.vaccine.2011.09.023.View ArticlePubMedGoogle Scholar
- Burridge MJ, Kimber CD: The indirect fluorescent antibody test for experimental East Coast fever (Theileria parva infection of cattle). Evaluation of a cell culture schizont antigen. Res Vet Sci. 1972, 13: 451-455.PubMedGoogle Scholar
- Torina A, Khoury C, Caracappa S, Maroli M: Ticks infesting livestock on farms in Western Sicily, Italy. Exp Appl Acarol. 2006, 38: 75-86. 10.1007/s10493-005-5629-1.View ArticlePubMedGoogle Scholar
- Torina A, Alongi A, Naranjo V, Estrada-Peña A, Vicente J, Scimeca S, Marino AMF, Salina F, Caracappa S, de la Fuente J: Prevalence and genotypes of Anaplasma species and habitat suitability for ticks in a Mediterranean ecosystem. Appl Env Microbiol. 2008, 74: 7578-7584. 10.1128/AEM.01625-08.View ArticleGoogle Scholar
- Merino M, Antunes S, Mosqueda J, Moreno-Cid JA, de la Lastra JM P, Rosario-Cruz R, Rodríguez S, Domingos A, de la Fuente J: Vaccination with proteins involved in tick-pathogen interactions reduces vector infestations and pathogen infection. Vaccine. 2013, in pressGoogle Scholar
- de la Fuente J, Torina A, Caracappa S, Tumino G, Furlá R, Almazán C, Kocan KM: Serologic and molecular characterization of Anaplasma species infection in farm animals and ticks from Sicily. Vet Parasitol. 2005, 133: 357-362. 10.1016/j.vetpar.2005.05.063.View ArticlePubMedGoogle Scholar
- Torina A, Vicente J, Alongi A, Scimeca S, Turlá R, Nicosia S, Di Marco V, Caracappa S, de la Fuente J: Observed prevalence of tick-borne pathogens in domestic animals in Sicily, Italy during 2003–2005. Zoonoses Public Health. 2007, 54: 8-15. 10.1111/j.1863-2378.2007.00989.x.View ArticlePubMedGoogle Scholar
- Torina A, Alongi A, Scimeca S, Vicente J, Caracappa S, de la Fuente J: Prevalence of tick-borne pathogens in ticks in Sicily. Transb Emerg Dis. 2010, 57: 46-48. 10.1111/j.1865-1682.2010.01101.x.View ArticleGoogle Scholar
- Villar M, Torina A, Nuñez Y, Zivkovic Z, Marina A, Alongi A, Scimeca S, La Barbera G, Caracappa S, Vázquez J, de la Fuente J: Application of highly sensitive saturation labeling to the analysis of differential protein expression in infected ticks from limited samples. Proteome Sci. 2010, 8: 43-10.1186/1477-5956-8-43.PubMed CentralView ArticlePubMedGoogle Scholar
- Capuano F, Landolfi MC, Monetti DM: Influence of three types of farm management on the seroprevalence of Q fever as assessed by an indirect immunofluorescence assay. Vet Rec. 2001, 149: 669-671. 10.1136/vr.149.22.669.View ArticlePubMedGoogle Scholar
- Georgiev M, Afonso A, Neubauer H, Needham H, Thiery R, Rodolakis A, Roest H, Stark K, Stegeman J, Vellema P, van der Hoek W, More S: Q fever in humans and farm animals in four European countries, 1982 to 2010. Euro Surveill. 2013, 18 (8): pii=20407-Google Scholar
- Torina A, Galindo RC, Vicente J, Di Marco V, Russo M, Aronica V, Fiasconaro M, Scimeca S, Alongi A, Caracappa S, Kocan KM, Gortazar C, de la Fuente J: Characterization of Anaplasma phagocytophilum and A. ovis infection in a naturally infected sheep flock with poor health condition. Trop Anim Health Prod. 2010, 42: 1327-1331. 10.1007/s11250-010-9580-8.View ArticlePubMedGoogle Scholar
- Kocan KM, de la Fuente J, Blouin EF, Coetzee JF, Ewing SA: The Natural History of Anaplasma marginale. Vet Parasitol. 2010, 167: 95-107. 10.1016/j.vetpar.2009.09.012.View ArticlePubMedGoogle Scholar
- de la Fuente J, Torina A, Naranjo V, Caracappa S, Vicente J, Mangold AJ, Vicari D, Alongi A, Scimeca S, Kocan KM: Genetic diversity of Anaplasma marginale strains from cattle farms with different husbandry systems in the Province of Palermo, Sicily. J Vet Med B. 2005, 52: 226-229. 10.1111/j.1439-0450.2005.00851.x.View ArticleGoogle Scholar
- De la Fuente J, Ruybal P, Mtshali MS, Naranjo V, Shuqing L, Mangold AJ, Rodríguez SD, Jiménez R, Vicente J, Moretta R, Torina A, Almazán C, Mbati PM, Torioni De Echaide S, Farber M, Rosario-Cruz R, Gortazar C, Kocan KM: Analysis of world strains of Anaplasma marginale using major surface protein 1a repeat sequences. Vet Microbiol. 2007, 119: 382-390. 10.1016/j.vetmic.2006.09.015.View ArticlePubMedGoogle Scholar
- Cabezas-Cruz A, Passos LMF, Lis K, Kenneil R, Valdés JJ, Ferrolho J, Tonk M, Pohl AE, Grubhoffer L, Zweygarth E, Shkap V, Ribeiro MFB, Estrada-Peña A, Kocan KM, de la Fuente J: Functional and immunological relevance of Anaplasma marginale major surface protein 1a sequence and structural analysis. PLoS ONE. 2013, 8 (6): e65243-10.1371/journal.pone.0065243.PubMed CentralView ArticlePubMedGoogle Scholar
- de la Fuente J, Atkinson MW, Naranjo V, de Mera IG F, Mangold AJ, Keating KA, Kocan KM: Sequence analysis of the msp4 gene of Anaplasma ovis strains. Vet Microbiol. 2007, 119: 375-381. 10.1016/j.vetmic.2006.09.011.View ArticlePubMedGoogle Scholar
- de León AA P, Strickman DA, Knowles DP, Fish D, Thacker E, de la Fuente J, Krause P, Wikel SK, Miller RS, Wagner GG, Almazán C, Hillman R, Messenger MT, Ugstad PO, Duhaime RA, Teel PD, Ortega-Santos A, Hewitt DG, Bowers EJ, Bent S, Cochran MH, McElwain TF, Scoles GA, Suarez CE, Davey R, Howell Freeman JM, Lohmeyer K, Li A, Guerrero F, Kammlah D, Phillips P, Pound JM: for the Group for Emerging Babesioses and One Health Research and Development in the U.S. One health approach to identify research needs in bovine and human babesioses: Workshop report. Parasit Vectors. 2010, 3: 36-10.1186/1756-3305-3-36.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.